Multidisciplinary | Home

Malaysia
Search
Sign In

Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Relugolix represents oral alternative to injectable androgen deprivation therapies

an hour ago

In patients with localized prostate cancer undergoing external beam radiotherapy, use of the orally administered androgen deprivation therapy relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.

No need for adult tetanus, diphtheria boosters if fully vaccinated in childhood

Pearl Toh, 15 hours ago

Adults do not need booster shots for tetanus or diphtheria if they have already completed their vaccination course against these diseases during childhood, a study suggests.

Capsule endoscopy feasible for iron deficiency anaemia diagnosis

18 hours ago

The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.

Tamsulosin plus mirabegron proven safe, effective in men with overactive bladder

19 hours ago

Mirabegron add-on therapy is both safe and effective in the treatment of men with overactive bladder symptoms receiving tamsulosin for benign prostatic hyperplasia, according to the results of a randomized, phase IV study.

Activated vitamin D significantly improves bone mineral density in osteoporotic patients

21 May 2020

At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).

Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm

11 May 2020

This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.

Sacubitril/valsartan prevents hospital readmission in a patient with HF following AMI

05 May 2020

Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.¹ Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.^2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.

Ticagrelor benefits in TWILIGHT hold up in diabetes

Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Ticagrelor monotherapy outshines DAPT after complex PCI

Audrey Abella, 23 Apr 2020

Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.

TICO backs ticagrelor alone in ACS post-PCI

Pearl Toh, 23 Apr 2020

Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.

Contraception with LNG-IUD still effective up to 6 years

Pearl Toh, 21 May 2020

A levonorgestrel (LNG)-releasing intrauterine device (IUD) maintains high contraceptive efficacy up to 6 years, which is beyond the 5-year period it is currently approved for, according to data from the Mirena Extension Trial (MET) released during the ACOG 2020 Meeting.

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Dupilumab reduces pruritus, anxiety, depression in atopic dermatitis

Roshini Claire Anthony, 18 May 2020

Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

DTG/FTC/TAF a suitable ART regimen in pregnancy

Roshini Claire Anthony, 14 May 2020

The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

Audrey Abella, 14 May 2020

The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.

Second patient cured of HIV through stem cell transplant

Pearl Toh, 13 May 2020

The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!